Large randomized prostate cancer clinical trials over the past 20 years have under‐represented racial minorities. It will be critical in the future to ensure that the patients enrolled in trials are representative of the general population, so that clinicians can provide optimal therapy for patients.
No takes yet. Share an insight, caveat, or question.
Galsky et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: